Tcs Biosciences Limited

POWER SEARCH PRICING

SOLUTIONS

tcs biosciences limited Company Information

Company Number

02172900

Next Accounts

Aug 2025

Directors

Lynda Preston

Emily Utley

View All

Shareholders

lynda jane preston

james preston

View All

Group Structure

View All

Industry

Manufacture of basic pharmaceutical products

Registered Address

botolph farm, botolph claydon, buckingham, MK18 2LR

Website

www.tcsbiosciences.co.uk

tcs biosciences limited Estimated Valuation

£17m

Pomanda estimates the enterprise value of TCS BIOSCIENCES LIMITED at £17m based on Net Assets of £9.5m and 1.78x industry multiple (adjusted for liquidity).

Edit your figures and get a professional valuation report.

Tcs Biosciences Limited is a live company located in buckingham, MK18 2LR with a Companies House number of 02172900. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in October 1987, it's largest shareholder is lynda jane preston with a 25.2% stake. Tcs Biosciences Limited is a mature, mid sized company, Pomanda has estimated its turnover at £9.3m with declining growth in recent years.

View Sample

Upgrade for unlimited company reports & a free credit check

Pomanda's financial health check has awarded Tcs Biosciences Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 4 areas for improvement. Company Health Check FAQs

Health Rating5out of 5

4 Strong

4 Regular

4 Weak

Size

annual sales of £9.3m, make it smaller than the average company (£33.9m)

Growth

3 year (CAGR) sales growth of -20%, show it is growing at a slower rate (5%)

EXPORT

Tcs Biosciences Limited's latest turnover from November 2023 is estimated at £9.3 million and the company has net assets of £9.5 million. According to their latest financial statements, Tcs Biosciences Limited has 46 employees and maintains cash reserves of £6.6 million as reported in the balance sheet.

Data source: Companies House, Pomanda Estimates

	Nov 2023	Nov 2022	Nov 2021	Nov 2020	Nov 2019	Nov 2018	Nov 2017	Nov 2016	Nov 2015	Nov 2014	Nov 2013	Nov 2012	Nov 2011	Nov 2010	Nov 2009
Turnover	9,270,755	8,745,120	7,719,864	18,423,845	16,724,210	26,738,006	19,687,553	24,971,593	12,109,856	16,250,272	12,809,593	5,798,702	6,123,576	4,720,885
Other Income Or Grants
Cost Of Sales	5,717,810	5,522,355	4,659,097	11,530,571	10,156,593	16,274,490	12,393,013	15,310,084	7,055,408	10,108,538	8,104,285	3,679,513	3,744,309	2,951,735
Gross Profit	3,552,945	3,222,765	3,060,767	6,893,274	6,567,617	10,463,516	7,294,541	9,661,509	5,054,448	6,141,734	4,705,308	2,119,189	2,379,267	1,769,150
Admin Expenses	2,475,430	1,771,918	2,310,665	6,628,776	6,621,972	9,747,757	6,289,928	8,820,121	4,352,598	5,333,604	4,200,754	1,653,570	1,968,329	1,232,624	-2,251,177
Operating Profit	1,077,515	1,450,847	750,102	264,498	-54,355	715,759	1,004,613	841,388	701,850	808,130	504,554	465,619	410,938	536,526	2,251,177
Interest Payable
Interest Receivable	304,334	142,272	3,548	2,458	24,747	29,839	17,025	6,706	11,568	9,566	6,281	6,029	6,757	7,083	3,594
Pre-Tax Profit	1,381,849	1,593,119	753,651	266,956	-29,608	745,598	1,021,638	848,094	713,418	817,696	510,835	471,649	417,695	543,608	2,254,771
Tax	-345,462	-302,693	-143,194	-50,722		-141,664	-194,111	-169,619	-142,683	-171,716	-117,492	-113,196	-108,601	-152,210	-631,336
Profit After Tax	1,036,387	1,290,426	610,457	216,234	-29,608	603,934	827,527	678,475	570,734	645,980	393,343	358,453	309,094	391,398	1,623,435
Dividends Paid
Retained Profit	1,036,387	1,290,426	610,457	216,234	-29,608	603,934	827,527	678,475	570,734	645,980	393,343	358,453	309,094	391,398	1,623,435
Employee Costs	2,853,006	2,827,890	2,836,325	2,704,155	2,841,255	2,684,053	2,560,435	2,266,704	2,664,419	3,597,600	2,776,042	1,114,380	1,200,079	933,857
Number Of Employees	46	45	45	43	48	48	49	49	55	84	67	28	31	24
EBITDA*	1,137,482	1,505,506	807,818	793,752	27,795	800,990	1,072,966	897,816	754,027	844,543	535,640	504,148	554,284	543,871	2,296,222

* Earnings Before Interest, Tax, Depreciation and Amortisation

	Nov 2023	Nov 2022	Nov 2021	Nov 2020	Nov 2019	Nov 2018	Nov 2017	Nov 2016	Nov 2015	Nov 2014	Nov 2013	Nov 2012	Nov 2011	Nov 2010	Nov 2009
Tangible Assets	724,621	607,605	592,817	567,787	540,733	464,628	259,931	268,518	247,972	202,320	207,644	224,575	203,135	217,794	252,677
Intangible Assets														116,648	233,324
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets	724,621	607,605	592,817	567,787	540,733	464,628	259,931	268,518	247,972	202,320	207,644	224,575	203,135	334,442	486,001
Stock & work in progress	1,757,884	1,155,064	980,843	793,993	1,321,754	710,070	1,212,528	786,108	714,811	507,215	563,837	485,923	572,907	487,963	494,776
Trade Debtors	1,155,286	1,280,444	830,268	3,977,516	3,499,774	5,954,450	4,378,010	5,971,766	2,721,188	3,196,318	2,776,984	1,304,517	1,229,523	773,531	1,457,531
Group Debtors	380,885	458,545
Misc Debtors	78,072	641,934	1,077,866	822,092	784,334	462,758	538,723
Cash	6,586,196	5,007,491	4,477,299	2,619,637	2,296,118	4,303,114	3,653,862	3,156,173	2,208,734	2,418,298	1,408,102	1,104,492	1,307,224	1,395,570	1,437,527
misc current assets	966,228	841,229	841,229	841,229	1,265,533	797,174	266,870	266,870	266,870	218,069	189,035	138,984	75,424	50,440	20,855
total current assets	10,924,551	9,384,707	8,207,505	9,054,467	9,167,513	12,227,566	10,049,993	10,180,917	5,911,603	6,339,900	4,937,958	3,033,916	3,185,078	2,707,504	3,410,689
total assets	11,649,172	9,992,312	8,800,322	9,622,254	9,708,246	12,692,194	10,309,924	10,449,435	6,159,575	6,542,220	5,145,602	3,258,491	3,388,213	3,041,946	3,896,690
Bank overdraft
Bank loan
Trade Creditors	975,967	604,767	966,984	2,683,940	2,867,880	5,723,219	3,843,132	5,477,523	1,866,138	2,819,517	2,068,879	575,111	1,063,286	1,026,113	2,272,255
Group/Directors Accounts		158,920	51,416	58,866	155,871	77,359	65,342
other short term finances
hp & lease commitments
other current liabilities	1,070,465	737,743	581,466	289,449	310,730	488,243	602,011
total current liabilities	2,046,432	1,501,430	1,599,866	3,032,255	3,334,481	6,288,821	4,510,485	5,477,523	1,866,138	2,819,517	2,068,879	575,111	1,063,286	1,026,113	2,272,255
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions	75,471
total long term liabilities	75,471
total liabilities	2,121,903	1,501,430	1,599,866	3,032,255	3,334,481	6,288,821	4,510,485	5,477,523	1,866,138	2,819,517	2,068,879	575,111	1,063,286	1,026,113	2,272,255
net assets	9,527,269	8,490,882	7,200,456	6,589,999	6,373,765	6,403,373	5,799,439	4,971,912	4,293,437	3,722,703	3,076,723	2,683,380	2,324,927	2,015,833	1,624,435
total shareholders funds	9,527,269	8,490,882	7,200,456	6,589,999	6,373,765	6,403,373	5,799,439	4,971,912	4,293,437	3,722,703	3,076,723	2,683,380	2,324,927	2,015,833	1,624,435

	Nov 2023	Nov 2022	Nov 2021	Nov 2020	Nov 2019	Nov 2018	Nov 2017	Nov 2016	Nov 2015	Nov 2014	Nov 2013	Nov 2012	Nov 2011	Nov 2010	Nov 2009
Operating Activities
Operating Profit	1,077,515	1,450,847	750,102	264,498	-54,355	715,759	1,004,613	841,388	701,850	808,130	504,554	465,619	410,938	536,526	2,251,177
Depreciation	59,967	54,659	57,716	54,254	82,150	85,231	68,353	56,428	52,177	36,413	31,086	38,529	26,698	7,345	45,045
Amortisation				475,000									116,648
Tax	-345,462	-302,693	-143,194	-50,722		-141,664	-194,111	-169,619	-142,683	-171,716	-117,492	-113,196	-108,601	-152,210	-631,336
Stock	602,820	174,221	186,850	-527,761	611,684	-502,458	426,420	71,297	207,596	-56,622	77,914	-86,984	84,944	-6,813	494,776
Debtors	-766,680	472,789	-2,891,474	515,500	-2,133,100	1,500,475	-1,055,033	3,250,578	-475,130	419,334	1,472,467	74,994	455,992	-684,000	1,457,531
Creditors	371,200	-362,217	-1,716,956	-183,940	-2,855,339	1,880,087	-1,634,391	3,611,385	-953,379	750,638	1,493,768	-488,175	37,173	-1,246,142	2,272,255
Accruals and Deferred Income	332,722	156,277	292,017	-21,281	-177,513	-113,768	602,011
Deferred Taxes & Provisions	75,471
Cash flow from operations	1,735,273	349,863	1,944,309	550,070	-1,483,641	1,427,628	475,088	1,017,707	-74,501	1,060,753	361,535	-85,233	-58,080	-163,668	1,984,834
Investing Activities
capital expenditure	-176,983	-69,447	-82,746	-556,308	-158,255	-289,928	-59,766	-76,974	-97,829	-31,089	-14,155	-59,969	-12,039	144,214	-531,046
Change in Investments
cash flow from investments	-176,983	-69,447	-82,746	-556,308	-158,255	-289,928	-59,766	-76,974	-97,829	-31,089	-14,155	-59,969	-12,039	144,214	-531,046
Financing Activities
Bank loans
Group/Directors Accounts	-158,920	107,504	-7,450	-97,005	78,512	12,017	65,342
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue															1,000
interest	304,334	142,272	3,548	2,458	24,747	29,839	17,025	6,706	11,568	9,566	6,281	6,029	6,757	7,083	3,594
cash flow from financing	145,414	249,776	-3,902	-94,547	103,259	41,856	82,367	6,706	11,568	9,566	6,281	6,029	6,757	7,083	4,594
cash and cash equivalents
cash	1,578,705	530,192	1,857,662	323,519	-2,006,996	649,252	497,689	947,439	-209,564	1,010,196	303,610	-202,732	-88,346	-41,957	1,437,527
overdraft
change in cash	1,578,705	530,192	1,857,662	323,519	-2,006,996	649,252	497,689	947,439	-209,564	1,010,196	303,610	-202,732	-88,346	-41,957	1,437,527

Very Low Risk70 - 100

Low Risk50 - 70

Moderate Risk30 - 50

High Risk20 - 30

Very High Risk0 - 20

Get a comprehensive credit check for tcs biosciences limited. Get real-time insights into tcs biosciences limited's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Perform a competitor analysis for tcs biosciences limited by selecting its closest rivals, whether from the MANUFACTURING sector, other mid companies, companies in MK18 area or any other competitors across 12 key performance metrics.

TCS BIOSCIENCES LIMITED group structure

Tcs Biosciences Limited has no subsidiary companies.

Ultimate parent company

TCS BIOSCIENCES LIMITED

02172900

TCS BIOSCIENCES LIMITED Shareholders

lynda jane preston	25.18%
james preston	24.94%
katherine elaine langston	24.94%
emily jane utley	24.94%

Tcs Biosciences Limited currently has 5 directors. The longest serving directors include Mrs Lynda Preston (Apr 2001) and Ms Emily Utley (Sep 2005).

officer	country	age	start	end	role
Mrs Lynda Preston	England	77 years	Apr 2001	-	Director
Ms Emily Utley		53 years	Sep 2005	-	Director
Dr Kate Langston		52 years	Sep 2005	-	Director
Mr Gareth Williams		47 years	Apr 2006	-	Director
Mr James Preston	England	38 years	May 2017	-	Director

P&L

November 2023

turnover

9.3m

+6%

operating profit

1.1m

gross margin

38.4%

+3.99%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

November 2023

net assets

9.5m

+0.12%

total assets

11.6m

+0.17%

cash

6.6m

+0.32%

net assets

Total assets minus all liabilities

Similar Companies

cross healthcare limited

g.r. lane health products limited

3.5

macopharma (uk) limited

pharmapac (u.k.) limited

aesica pharmaceuticals limited

company number

02172900

Type

Private limited with Share Capital

industry

21100 - Manufacture of basic pharmaceutical products

incorporation date

October 1987

ultimate parent company

None

previous names

medical & veterinary supplies limited (April 2001)

cordback limited (December 1987)

address

botolph farm, botolph claydon, buckingham, MK18 2LR

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We found 5 charges/mortgages relating to tcs biosciences limited. Currently there are 2 open charges and 3 have been satisfied in the past.

When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.

Click to start generating capital raising & share issue transactions for TCS BIOSCIENCES LIMITED. This can take several minutes, an email will notify you when this has completed.

tcs biosciences limited Company Information

tcs biosciences limited Estimated Valuation

tcs biosciences limited Estimated Valuation

tcs biosciences limited Estimated Valuation

Tcs Biosciences Limited Overview

Tcs Biosciences Limited Health Check

TCS BIOSCIENCES LIMITED financials

tcs biosciences limited Credit Report and Business Information

Tcs Biosciences Limited Competitor Analysis

tcs biosciences limited Ownership

tcs biosciences limited directors

tcs biosciences limited company details

tcs biosciences limited Charges & Mortgages

tcs biosciences limited Capital Raised & Share Issues BETA

tcs biosciences limited Companies House Filings - See Documents